Board of Directors

Doug McCormack

Doug is Executive Chairman of modus health and also serves as Chairman of Orthocare Innovations, a company that he co-founded and served as CEO from inception through completion of a significant transaction with a strategic partner and global player in the field, Ottobock.   Prior to focusing on building early stage companies, Doug spent sixteen years working at the intersection of politics, policy, law, and business advising organizations and corporations, ranging from early stage medical technology companies to large health systems, achieve strategic growth objectives. A recognized Washington, D.C. advocate and strategist, Doug was a partner in the international law firm of Sonnenschein, Nath & Rosenthal, practicing as a public policy and health care lawyer in the firm’s Washington office. Prior to this position he was an associate at the Washington, D.C. firm Arent Fox and Vice President at the federal consulting subsidiary of Baker and Daniels. Doug received his BA from the University of Southern California, and earned his JD from the American University Washington College of Law. He recently completed a five-year term on the Defense Health Board as an appointee of the U.S. Secretary of Defense.

Jay Althoff

Jay joined modus health as CEO in June 2015. For the past 15 years, Jay has focused on early stage companies, most recently leading PlanetTran, a green transportation company, as CEO. Prior to that, Jay served as Chief Development Officer of Zeo, an early innovator in the personal health data field that was focused on sleep data, and as Chief Strategy Officer of Circle Company Associates, which was during his tenure the leading concierge and experiential marketing company in the US. Previously, Jay was VP and General Counsel of Ekco Group, Inc., then a public consumer products company, a Corporate Associate at Ropes & Gray, a leading Boston law firm, and an Investment Banking Associate in the Capital Markets Group of Westpac Banking Corporation, a leading international bank based in Australia. Jay received his BA from Connecticut College and his JD from The George Washington University.

Peter Binas

Peter joined Schooner Capital in 2008 as a Managing Director after almost ten years with management consultancy McKinsey & Company. While there, Peter specialized in corporate finance and strategy, advising leading players in the consumer packaged goods and retail industries in the US, Latin America, and Western Europe. Core areas of focus included mergers and acquisitions, new market entry and growth strategies, competitive strategy, post-merger integration, and operational effectiveness. At Schooner, Peter serves as a director on the boards of RailComm, Colo Railroad Builders, Orthocare Innovations, and CustomMade. He also provides strategic and corporate finance support across the full portfolio. Peter holds a JD/MBA from Harvard Law and from Harvard Business School where he was a Baker scholar, and an AB with Honors from Harvard University where he graduated Phi Beta Kappa in Economics and Social Studies.

David Boone, PhD, MPH, CP

David Boone, Co-founder, Chief Technology Officer and President of Orthocare Innovations, has spent the past twenty years as an innovator, developer, researcher, and instructor in rehabilitation and bioengineering. A frequent lecturer at academic medical centers on a range of prosthetic and rehabilitation topics and a widely published author, he is credited with multiple technology patents, including a foot scanning technology that was licensed to Nike.  He also was the principal developer of a range of innovative lower limb prosthetics products and technologies that were sold and/or licensed via Orthocare’s partnership with Ottobock, a global medical device company based in Germany.

David received his PhD in Bioengineering from The Hong Kong Polytechnic University and became one of fewer than ten American PhDs with formal training and clinical experience in prosthetics. He began his work in in the field under the direction of a pioneer in the field, Dr. Ernest Burgess, and later assumed leadership of Dr. Burgess’ lab, Prosthetic Research Study (PRS) in Seattle. It was in this capacity that he led the development team that created the StepWatch technology. David was recently named Editor-in-Chief of the Journal of Prosthetics and Orthotics by the American Academy of Orthotists and Prosthetists.

Ted Henderson

Ted has been a Managing Director at Schooner Capital since 2004. Along with his colleagues, Ted invests across asset classes, domestically and abroad, with particular interest in domestic venture and growth stage companies, as well as alternative asset holdings in developing markets. Presently, Ted serves as a director at Orthocare Innovations, MediaSilo, Millstone Medical Outsourcing, Nanoscale Powders, Seventh Generation, SRS Medical, Topokine Therapeutics, and Zixi. At Millstone Medical Outsourcing and Zixi, he serves as chairman. He is a past director of a number of Schooner investments, as well as several not-for-profit organizations. Prior to joining Schooner, Ted founded several enterprises in the for-profit education sector, served as a general manager at subsidiaries of The Washington Post Company, worked in venture capital at Fidelity Capital, and served global clients at Leo Burnett. Ted received an MBA from Harvard Business School and is a cum laude graduate of Dartmouth College, with a degree in Chinese language and culture.

Corporate Advisory Board

David Albert, MD

David E.  Albert, MD is a physician, inventor, and serial entrepreneur who has developed medical and other life-saving technologies and products over the last 30 years, turning a number of those innovations into tech startups. Today, he is a founder of three tech companies: InnovAlarm, Lifetone Technology, and AliveCor. His previous startups include Corazonix Corp (sold to Arrhythmia Research Technology) and Data Critical (sold to GE). Dr.  Albert left GE in 2004 as Chief Scientist of GE Cardiology to disrupt several new markets. His latest invention, the iPhone ECG, became a global sensation via a 4-minute YouTube Video in January around the Consumer Electronics Show and was featured on local media, ABC, CBS, CNN, and Fox News among many other media outlets. Dr.  Albert has 37 issued US patents, a large number pending, and several new “secret inventions” in development. He has authored or co-authored over 50 scientific abstracts and publications principally in Cardiology literature.  Also, Dr.  Albert has lectured at entrepreneurship programs at the MIT Sloan School and the University of Oklahoma. Dr.  Albert graduated with Honors from Harvard College and from Duke University Medical School.

Rimas Buinevicius

Mr. Buinevicius is a long time technology innovator and entrepreneur. He is the former CEO and Chairman of Sonic Foundry, Inc. (NASDAQ:SOFO) a Madison, WI-based technology company leading an effort to transform online education and knowledge training through the use of the Internet. For over 25 years, he has been involved with numerous early stage companies and has experience in the areas of technology, finance, business planning, and marketing. His industry background has included internet, high technology, medical device manufacturing, defense and aerospace, and industrial control markets all with the purpose of looking for market changing initiatives that provide a company with an edge. During his 14-year tenure as CEO of Sonic Foundry, he established a financial network of investors with an interest in early stage technology. He holds a BSEE from Illinois Institute of Technology, an MSEE from the University of Wisconsin-Madison and an Executive MBA from the University of Chicago.

Tim Ehrlich

Tim is a partner in Gunderson Dettmer’s Boston office where he focuses on the representation of start-up, emerging growth, and public companies in the information technology, biotech, and medical device industries. His practice spans the entire corporate lifecycle, from formation through liquidity. Tim is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, general corporate and governance matters, as well as M&A events and public offerings. In addition to his company client counsel, Tim represents a number of prominent venture capital funds and institutional investors in their financing activities. Tim has particular expertise in structuring and negotiating strategic alliances, including “bet-the-company” intellectual property collaborations, and joint ventures, and providing strategic counseling and advice regarding intellectual property protection and commercialization.  Prior to joining the firm Tim was previously a corporate counsel for Cisco Systems.   Tim currently serves as an advisor to the Harvard Law Entrepreneurship Program at Harvard Law School and the Harvard University iLab.  Tim received his JD cum laude from Harvard Law School, where he was an editor of the Harvard Journal of Law and Technology and his AB summa cum laude from Princeton University.  Since 2010 Tim has been named as a “New England Rising Star” by Super Lawyers magazine, and since 2012 he has been selected as a “Life Sciences Star” for his outstanding transactional work by LMG Life Sciences.

Bert Harman

Mr. Harman serves as President and CEO of Data Sciences International, a technology provider of complete systems for monitoring and collecting data including advanced telemetry implants and receivers along with data acquisition and analysis software. These systems represent a major advancement in data collection for pharmacological studies.  Prior to DSI, Mr. Harman served as President and CEO, Americas of Otto Bock HealthCare, a developer and manufacturer of advanced assistive technologies.  Mr. Harman spent the first twenty-five years of his career working in 3M’s Industrial, International, and Health Care Businesses.

Bob McDonald, MD

Robert C. McDonald, MD, MBA is the President and Founder of Aledo Consulting, Inc. Prior to this role, he served in a variety of senior medical and operations positions at Anthem Blue Cross and Blue Shield and its predecessor company, The Associated Group, including Medical Director of Medical Policy, Medical Director of Anthem Prescription Management, LLC, and Medical Director of Health Care Management, Anthem Inc. Among his responsibilities at Anthem were the creation and contracting of the first network of national scope for hemophilia factor and immunoglobulin providers. Prior to Anthem, he served for three years at Eli Lilly and Company as a Health Economics Research Physician performing cost effectiveness analyses both as part of developmental trials and on site at health plans across the United States. Dr. McDonald received his MD from University of Texas Southwestern Medical School and his MBA from the University of Pennsylvania Wharton School of Business.

Chuck O’Neill

Chuck has spent the past 20 years establishing and running new divisions for major corporations and founding new healthcare companies. In 2004, he co-founded Avalon Healthcare Holdings, Inc., a health insurance company offering consumer-directed health plans throughout Florida. Prior to creating and starting Avalon, Chuck was co-founder and director of Oxford Benefit Management (OBM), a wholly owned subsidiary of Oxford Health Plans. In 1999, he co-founded and served as co-CEO of Tech Health, Inc., a healthcare technology company acquired in 2013 for $150 million.  Prior to Tech Health, he served in corporate capacities with PharMerica, Inc. and Oxford Health Plans. Most recently he served in a leadership role with Connections, acquired by United Healthcare in 2012.

Bradley Merrill Thompson

Brad is a Member of the Firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory, reimbursement, and clinical trial issues. At the firm, Mr. Thompson leads the Medical Device Regulatory Practice, the Clinical Trials Initiative, and the Connected Health Initiative, and he serves on the firm’s National Health Care and Life Sciences Steering Committee.  In the Connected Health Initiative at the firm, Mr. Thomspon focuses on the federal regulatory requirements—FDA, reimbursement, privacy, and others—that impact remote monitoring, mobile health, HIT, and device interoperability. Mr. Thompson serves as a member of a workgroup, created by the U.S. Department of Health and Human Services (HHS) and the Federal Communications Commission (FCC), focusing on identifying key considerations to improve patient safety and promote innovation in health information technology, including mobile medical applications. On the working group, Mr. Thompson co-chairs the Regulations Subcommittee charged with identifying regulatory best practices for such technologies. Mr. Thompson also conducts educational programs on connected health regulation and blogs for

Scientific Advisory Board

Lee Dibble, PhD, PT, ATC

Dr. Dibble received his master’s degree in physical therapy from Duke University in 1991 and his doctoral degree in exercise and sport science from the University of Utah in 2001.  He is currently an Associate Professor within the Department of Physical Therapy from the University of Utah, Director of Parkinsonism Exercise Program, and Co-director of the motion analysis core facility. Dr. Dibble’s research focuses on the effect of Parkinson disease on postural control and falls, as well as the effect of exercise countermeasures as a means of minimizing these deficits. Through his participation as PI or co-investigator on previous and current grants, Dr. Dibble has developed the expertise in cross sectional studies, implementation of clinical trials of rehabilitative interventions, and longitudinal studies of the progression of disability. Dr. Dibble’s three long-term objectives are: 1) Characterize the benefits of exercise in neurodegenerative diseases in terms of central nervous system effect and alteration of the trajectory of disability. 2) Understand anticipatory and reactive postural control deficits in persons with neurodegenerative diseases. 3) Explore treatments targeted at augmenting sensory input, normalizing sensory integration, and improving motor output during postural reactions.

Andrew Gardner, PhD

Dr. Gardner received his doctoral degree in Exercise Science from Arizona State University in 1990.  Currently, Dr. Gardner is a Professor within the College of Medicine/Department of Geriatrics and the Donald W. Reynolds Chair of Aging Research. As an exercise physiologist with expertise in exercise rehabilitation and physiology related peripheral artery disease (PAD) and aging, Dr. Gardner has published high-impact studies that have focused on: (1) validating a treadmill exercise protocol to assess primary outcome measures used in many clinical trials world-wide, (2) randomized controlled clinical trials demonstrating the efficacy of supervised exercise programs to improve ambulatory function in patients with PAD and intermittent claudication, and (3) a recent randomized controlled clinical trial demonstrating the efficacy of a home-based exercise program to treat intermittent claudication.   In addition to his interest in PAD, Dr. Gardner studies the effects of co-morbid conditions and cardiovascular risk factors, such as metabolic syndrome, age and smoking on vascular function, physical activity and function and metabolic function in older adults.  This work has led to more than 135 peer-reviewed clinical research publications.

Dr. Gardner’s role at the Reynolds Oklahoma Center on Aging (ROCA) is to bridge the basic science research efforts of other faculty members in ROCA with clinical studies and the clinical research activities within the Department of Geriatric Medicine.  Dr. Gardner has established a collaborative network of vascular medicine specialists, cardiologists, and physicians at the University of Oklahoma Health Sciences campus and at the Oklahoma City VA Medical Center to provide a referral base of patients with PAD and other vascular diseases.  His research team is experienced in successfully recruiting patients, administering clinical research tests, conducting interventions, and retaining patients in randomized controlled trials.  Additional collaborations include clinical and translational studies in patients with vascular-mediated dementia and cognitive impairment.  Finally, the roles of vascular function, oxidative stress and inflammation with muscle function, gait, balance, and falls in older adults are a developing clinical and translational research approach that merges clinical faculty in the Department of Geriatric Medicine with basic scientists within the department.

George Fulk, PhD, PT

Dr. Fulk received his master’s degree in physical therapy from the University of Massachusetts and his doctoral degree in physical therapy from Nova Southeastern University in 2005. Dr. Fulk’s research projects have primarily focused on measuring and improving locomotor capability in people with stroke.  Specifically, his research has looked at methods of measuring walking ability and overall participation in people with stroke, interventions to improve walking ability in people with stroke and other neurological conditions, and the development and use of rehabilitation engineering technologies to enhance recovery in people with neurological disorders.  He has collaborated with engineering faculty to develop novel technologies that monitor walking activity and ambulatory assistive devices.

Thomas George Hornby, PhD, PT

Dr. Hornby received his doctoral degree in Physiological Sciences from the University of Arizona. He is a Research Assistant Professor at Northwestern University and Director of the Locomotor Recovery Laboratory at the Rehabilitation Institute of Chicago.

Dr. Hornby’s primary interests include improving locomotor function in individuals who have experienced motor impairments due to stroke or spinal cord injury (SCI). His research is integrative in that he focuses on new discoveries and on translation of these findings into rehabilitative protocols that can be implemented in the clinic. Past work has investigated the mechanisms underlying behavioral changes due to the use of robotics, body-weight-supported treadmill training, and pharmacologic agents, as well as their clinical efficacy.  Current research activities include looking at the acute and chronic effects of intensive locomotor training on endogenous neurotrophins that promote synaptic connectivity; electrophysiological studies of neural mechanisms underlying volitional force generation; pharmacological studies of various drugs and their effects on motor control; and interventional studies that employ task variability and high intensity training in order to maximize recovery of stepping activity in neurologically impaired individuals.